home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  October 28, 2020
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [4] [7] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 534 active entries

Institute for Biopharmaceutical Research (IBR)-Inc.

Lauchefeld 31
9548 Matzingen, Switzerland
Switzerland

Phone: +41 52 366 35 20
Fax: +41 52 366 35 21

E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Stock symbol: IBR-Inc.
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.

Description:

IBR Inc., Institute for Biopharmaceutical Research is a Swiss GxP-compliant contract research organization founded in 1998. We are a first-in-class site in the field of bioanalytical services for therapeutic antibodies, biologics, biosimilars, antibody-drug conjugates and vaccines covering the bioanalytical needs from pre-clinical to clinical development.

We are experienced in driving studies on cytokines, chemokines and other biomarkers, drug/target binding and immunogenicity. Furthermore, we perform cell-based assays with a broad variety of readouts. Our team has vast experience with primary cells, transformed cell lines, transfected cells, reporter-gene cell systems and 3D cell-based assays.

IBR Inc. moves on with rapid and constantly growing advances in technology and offers advanced platforms including Alpha Technology, Time Resolved Fluorescence (TRF), MSD® ECL, Gyrolab, BD FACS lyric state-of-the-art Flow Cytometry / Cytometric Bead Array and real time PCR, beside a broad variety of classical techniques.

With IBR Inc. your studies are supported from assay development to assay validation and sample measurement. We have capability to perform studies in compliance with regulatory guidelines for GLP and GCP quality standards, following the principles of ICH Q2 (R1), USP 1032, 1033 and 1034. Our study reports are compliant with eCTD requirements.



Selected Categories:
Product Company   Service Company
Consulting
- Research
- Software
Contract
- Research
- Services
Laboratory
- Analytical

Last update of this entry: August 28, 2018

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2020 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.